NASDAQ$VERA
Vera Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Vera Therapeutics reported third quarter 2021 financial results and provided a corporate update.
Vera Therapeutics reported a net loss of $7.6 million for the third quarter of 2021 and approximately $86.2 million in cash and cash equivalents as of September 30, 2021. The company is making progress in evaluating atacicept.
- Ongoing progress in several areas evaluating atacicept.
- Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a durable and substantial reduction in serum galactose-deficient IgA1 (Gd-IgA1) in a dose-dependent manner up to 72 weeks in patients with IgA nephropathy
- Vera reported approximately $86.2 million in cash and cash equivalents as of September 30, 2021
- Atacicept 75mg reduces Gd-IgA1 to the lowest risk quartile.
Headline financials
Revenue & EPS history
Vera · Revenue · Quarterly
$362K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
+0.2%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.2%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+15.6%
Q1 2022
Best reaction
-13.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +0.3% | -11.8% | |
| Q4 2025 | +1.5% | -5.7% | -6.8% | |
| Q3 2025 | +4.6% | +23.3% | +86.3% | |
| Q1 2025 | -13.5% | -15.0% | +20.0% | |
| Q4 2024 | +1.3% | -0.7% | -22.1% | |
| Q3 2024 | +0.3% | +1.3% | +1.1% | |
| Q2 2024 | +0.9% | +6.5% | +4.3% | |
| Q1 2024 | -8.1% | -9.1% | -14.3% | |
| Q4 2023 | -1.3% | -5.2% | -12.5% | |
| Q3 2023 | +5.4% | +18.2% | +18.9% | |
| Q2 2023 | -0.1% | -4.3% | -0.1% | |
| Q1 2023 | -1.7% | +0.0% | +0.9% | |
| Q4 2022 | +4.4% | +6.3% | -14.2% | |
| Q3 2022 | -3.2% | -3.8% | -2.1% | |
| Q2 2022 | +7.8% | +20.6% | +11.4% | |
| Q1 2022 | +15.6% | +11.4% | -8.5% | |
| Q4 2021 | +10.2% | +11.2% | +5.2% | |
| Q3 2021 | -11.6% | -7.1% | -3.3% | |
| Q2 2021 | +0.3% | +11.6% | +80.6% | |
| Q1 2021 | -7.6% | -13.6% | +11.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro